FUTURE OF HEALTHCARE

Trinity Health to Acquire CommonSpirit Health's Share of MercyOne Health System Become Sole Parent

Trinity Health | April 20, 2022

Trinity Health

Trinity Health and CommonSpirit Health announced they have signed an agreement for Trinity Health to acquire all facilities and assets of MercyOne, a regional health system based in Iowa. Since 1998, MercyOne has operated under a joint operating agreement between not-for-profit Catholic health care organizations Trinity Health and Catholic Health Initiatives, which is now CommonSpirit.

MercyOne is a leading health system in Iowa and serves more than 3.3 million patients each year. The system includes 16 medical centers, 27 affiliate organizations and more than 420 care sites offering a range of health and wellness services, including provider services and urgent care, and more than 20,000 colleagues including 2,000 of the state's most talented doctors and providers.

"True to our shared Catholic mission, our goal is to provide high-quality, compassionate care with the best patient/member experience possible. We will accomplish that goal through a holistic approach, with a range of health services and technologies that are fully connected and coordinated. This agreement creates a fully integrated MercyOne to care for more people in a unified way."

Mike Slubowski, president and chief executive officer at Trinity Health

After months of analysis and due diligence, Trinity Health and CommonSpirit determined a sole parent is the best path forward for MercyOne and for the communities it serves. Trinity Health, a national health system spanning 25 states, will bring unified strategies and operations to MercyOne's care sites, including one set of system services.

As an example, MercyOne will transition to Trinity Health's common platforms, including a single electronic health record (EHR), ultimately allowing patients to easily manage their care across all MercyOne services and facilities. The result is a more convenient and consistent care experience for MercyOne's communities.

"After two decades of successful collaboration, we are immensely proud of our partnership with Trinity Health and our efforts to advance health care statewide," said Marvin O'Quinn, president and chief operating officer at CommonSpirit Health. "While the current structure has been instrumental in growing our health care services in Iowa, we believe this decision is ultimately what is best for our patients, colleagues, and our communities."

"We strongly believe this transition to become a full member of the Trinity Health family will result in a stronger, more cohesive health system better able to offer a convenient and personalized circle of care for all we serve," said Bob Ritz, president and chief executive officer at MercyOne. "We are delighted to have the agreement in place as we plan for the future of our mission. We are grateful to CommonSpirit for more than 20 years of partnership."

Trinity Health and CommonSpirit will now plan for integration, complete regulatory filings, and take other steps necessary to finalize the transaction, which is expected to be completed summer 2022. This process will be seamless for the communities MercyOne serves, and patients can continue to expect the same compassionate care they have always received.

About Trinity Health

Trinity Health is one of the largest not-for-profit, Catholic health care systems in the nation. It is a family of 115,000 colleagues and nearly 26,000 physicians and clinicians caring for diverse communities across 25 states. Nationally recognized for care and experience, Trinity Health's network of care includes 88 hospitals, 131 continuing care locations, the second largest PACE program in the country, 125 urgent care locations, and many other health and well-being services. Based in Livonia, Michigan, its annual operating revenue is $20.2 billion with $1.2 billion returned to its communities in the form of charity care and other community benefit programs. For more information, visit www.trinity-health.org or follow us on LinkedIn, Facebook or Twitter.

About CommonSpirit Health

CommonSpirit Health is a nonprofit, Catholic health system dedicated to advancing health for all people. It was created in February 2019 by Catholic Health Initiatives and Dignity Health. With its national office in Chicago and a team of over 150,000 employees and 25,000 physicians and advanced practice clinicians, CommonSpirit operates 140 hospitals and more than 1,500 care sites across 21 states. In FY 2021, CommonSpirit had revenues of $33.3 billion and provided $5.1 billion in charity care, community benefit, and unreimbursed government programs. Learn more at www.commonspirit.org.

About MercyOne

MercyOne is a connected system of health care facilities and services dedicated to helping people and communities live their best life. MercyOne's care providers and staff make health the highest priority. The system's clinics, medical centers, hospitals and affiliates are located throughout the state of Iowa and beyond. Headquartered in central Iowa, MercyOne was founded in 1998 through a collaboration between Catholic Health Initiatives, now CommonSpirit Health, and Trinity Health - two of the country's foremost, not-for-profit Catholic health organizations.

Spotlight

The P&G Children’s Safe Drinking Water Programme, which has provided six billion litres of clean drinking water to 39 African countries in the past 11 years, will soon start making a difference in our country later this year, in partnership with Gift of the Givers...

Spotlight

The P&G Children’s Safe Drinking Water Programme, which has provided six billion litres of clean drinking water to 39 African countries in the past 11 years, will soon start making a difference in our country later this year, in partnership with Gift of the Givers...

Related News

HEALTH TECHNOLOGY

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

Novartis Pharma AG | September 19, 2022

Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individuals living with osteoporosis access to a more affordable, biosimilar version of this critical medicine, which may help to change the course of their disease.” Florian Bieber, Global Head of Development, Sandoz Biopharmaceuticals Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that has spread to the bone, and giant cell tumor of the bone2,3,4,5. The results from the integrated Phase I/III study confirm the biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in the respective indications; and contributes to demonstration of similarity, which is the basis for use in all indications. Approximately 500 million men and women worldwide may be affected by osteoporosis1, which causes 8.9 million fractures annually – or one fracture every three seconds1. By 2050, hip fractures are projected to increase by 240% in women and 310% in men compared to 19901. The results come soon after Sandoz confirmed acceptance of license applications for two other proposed biosimilars. In July 2022, the application for the first-of-a-kind multiple sclerosis proposed biosimilar natalizumab was accepted for review by the US Food and Drug Administration (FDA) and European Medicines Agency. In June 2022, the EMA and FDA accepted for review Sandoz applications for the high-concentration formulation 100 mg/mL (HCF) of its biosimilar adalimumab. Sandoz biosimilars help patients, in areas including immunology, oncology, nephrology, supportive care and endocrinology, access critical and potentially life-changing medicines sustainably and affordably. Sandoz has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. About ROSALIA6 In ROSALIA, 527 postmenopausal women with osteoporosis were randomized to receive either biosimilar denosumab or the reference medicine for up to 78 weeks of treatment. Objectives were to demonstrate similar efficacy in terms of change in lumbar spine bone mineral density, as well as similar pharmacokinetics and pharmacodynamics. The global clinical program for biosimilar denosumab was developed in consultation with major regulatory agencies and the results from this clinical study are expected to support regulatory approval. About denosumab Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue)2. By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in a reduction of bone loss, and subsequently the likelihood of fractures and other serious bone conditions2.

Read More

HEALTH TECHNOLOGY

Memorial Hermann Health System Invests in EnableComp, an Industry-Leading Specialty Revenue Cycle Management Solution

Memorial Hermann Health System | July 12, 2022

EnableComp has announced that Memorial Hermann Health System – a non-profit, community-focused, award-winning health system committed to creating healthier communities, now and for generations to come in the Houston area – has made a strategic investment in the company alongside Welsh, Carson, Anderson & Stowe. Based in Franklin, Tennessee, EnableComp leverages its proprietary software embedded with advanced AI+RPA capability, Enforcer360, to increase revenue yield and accelerate collections for healthcare providers on Veterans Administration, Workers' Compensation, Motor Vehicle Accident/Third-Party Liability, and Out-of-State Medicaid claims. EnableComp also offers comprehensive Denial Resolution, ensuring providers maximize cash collections and revenue recovery from underpayments and/or zero-balance accounts. Today, the company serves more than 1,000 healthcare providers across all 50 states. "We are very pleased to welcome Memorial Hermann as a health system investor partner. We look forward to working closely with their leadership to meet their needs and seek input on new product offerings. The investment enables us to continue to enhance our world-class Enforcer360 RCM technology platform, expand our product portfolio and ensure high-quality delivery of revenue cycle management solutions to the healthcare market." Randy Dobbs, EnableComp's Chief Executive Officer "As a non-profit, values-driven, community-owned health system, Memorial Hermann takes its dual roles of being a responsible financial steward and a trusted healthcare provider extremely seriously," said Feby Abraham, EVP and Chief Strategy Officer at Memorial Hermann Health System. "By making prudent investments in companies that align with our mission to improve health, we ensure we can continue meeting the needs of our Greater Houston community, one of the largest and fastest-growing metropolitan areas of the country, while also creating greater operational efficiencies. The decision to invest in EnableComp is guided by the same philosophies that drive all of our work: deliver value and create healthier communities. EnableComp fits squarely in that mission, with best-in-class solutions delivering compelling ROI and support, allowing health systems to focus on providing care to patients." Memorial Hermann is one of the largest not-for-profit health systems in Southeast Texas. While practicing the highest standards of safe, evidence-based, quality care, the system's 6,500 affiliated physicians and 29,000 employees provide a personalized and outcome-oriented experience across more than 265 care delivery sites throughout the Greater Houston area. Memorial Hermann will participate in EnableComp's Strategic Advisory Board to support growth initiatives, continuous quality improvement, new product development and expansion of capabilities. About Memorial Hermann Health System Charting a better future. A future that's built upon the HEALTH of our community. This is the driving force for Memorial Hermann, redefining health care for the individuals and many diverse populations we serve. Our 6,500 affiliated physicians and 29,000 employees practice the highest standards of safe, evidence-based, quality care to provide a personalized and outcome- oriented experience across our more than 265 care delivery sites. As one of the largest not-for- profit health systems in Southeast Texas, Memorial Hermann has an award-winning and nationally acclaimed Accountable Care Organization, 17* hospitals and numerous specialty programs and services conveniently located throughout the Greater Houston area. Memorial Hermann-Texas Medical Center is one of the nation's busiest Level I trauma centers and serves as the primary teaching hospital for McGovern Medical School at UTHealth Houston. For more than 115 years, our focus has been the best interest of our community, contributing more than $400 million annually through school-based health centers and other community benefit programs. Now and for generations to come, the health of our community will be at the center of what we do – charting a better future for all. About EnableComp EnableComp partners with over 1,000 healthcare providers to manage Veterans Administration, Workers' Compensation, Motor Vehicle Accident/TPL, and Out of State Medicaid claims, as well as ERISA appeals. EnableComp also offer services for A/R management, zero balance recovery, and commercial and government denials. The company's industry leading technology and analytics identifies the right payer, at the right time, for the right amount, ensuring clients collect the appropriate revenue for their complex claims and denials. EnableComp is also among the top one percent of companies to make the Inc. 5000 list of the fastest-growing private companies in the United States for the last eight years. About Welsh, Carson, Anderson & Stowe WCAS is a leading U.S. private equity firm focused on two target industries: technology and healthcare. Since its founding in 1979, the firm's strategy has been to partner with outstanding management teams and build value for its investors through a combination of operational improvements, growth initiatives and strategic acquisitions. The firm has raised and managed funds totaling over $30 billion of committed capital.

Read More

HEALTH TECHNOLOGY

NextGen Healthcare Expands Relationship with InstaMed to Simplify Payment Processing for Patients and Providers

NextGen Healthcare, Inc. | July 19, 2022

NextGen Healthcare, Inc, a leading provider of innovative, cloud-based healthcare technology solutions, announced that it has expanded its long-term relationship with InstaMed, a J.P. Morgan company, in a deal that modernizes payment processing through NextGen® Pay powered by InstaMed. This solution expands payment options and convenience for patients, who can pay online when visiting providers that utilize the NextGen® Practice Management solution. The platform also enables healthcare practices to automate collections and manage and view payments all in one system. The payment solution is not only convenient but secure, utilizing best-in-class data encryption protections. “With NextGen Pay powered by InstaMed, we’re taking the friction out of the patient-provider payment experience. Patients want a simple and streamlined process for paying their medical bills; providers want to focus on delivering the best care possible without being mired in collection inefficiencies. Our integrated solution delivers on both needs.” Srinivas (Sri) Velamoor, chief growth and strategy officer for NextGen Healthcare InstaMed is an industry leader in collecting healthcare payments throughout the patient journey. A recent trends report published by InstaMed highlights the importance of payment convenience to patients. According to the survey, 83% of patients want to continue using virtual and self-service options for care post-pandemic. Another 74% prefer online payment for medical bills. Additionally, 74% of millennials would switch providers for a better healthcare payment experience. “The expansion of our work with NextGen Healthcare is the evolution of our longstanding relationship rooted in delivering better healthcare payment experiences for both providers and patients,” said Jon Neal, head of business development at InstaMed and managing director at J.P.Morgan. “The demand and need for digital, automated and simple payment processes have never been higher. We are excited to see our solution drive real change for providers and patients.” Several NextGen Healthcare clients are already benefiting from NextGen Pay powered by InstaMed, which allows patients the convenience of saving credit card information within the online portal for quick payments on the go. With the expanded relationship, patients will also have the option to use Apple Pay® mobile payment solutions or Google Pay™ payment services at in-person care visits. “Now, our practice is a one-stop shop for patient collections,” said Matthew Pierre, chief executive officer of Loden Vision Centers, a NextGen Healthcare client based in Nashville. “The billing department can manage, view and collect payments all in one place. NextGen Pay powered by InstaMed improves the entire payment process, start to finish.” A webinar titled Trends in Healthcare Payments Annual Report: A Roadmap to the Future, set for July 21 at 2 p.m. EST, will delve into survey results and trends. Click here to register. About NextGen Healthcare, Inc. NextGen Healthcare, Inc. is a leading provider of innovative healthcare technology solutions. We are reimagining ambulatory healthcare with award-winning solutions that enable high-performing practices to create healthier communities. We partner with medical, behavioral and dental providers in their journey toward whole person health and value-based care. Our highly integrated, intelligent and interoperable solutions go beyond EHR and Practice Management to increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a quest to achieve better healthcare outcomes for all. About InstaMed InstaMed, a J.P. Morgan company, is part of the firm’s Healthcare Payments business that supports clients across the Corporate and Investment Bank, Commercial Bank and Chase Business Bank. J.P. Morgan Healthcare Payments has integrated InstaMed’s solutions to deliver an end-to-end suite of payments, treasury, and banking solutions to healthcare organizations of all sizes. InstaMed powers a better healthcare payments experience and connects consumers, providers and payers for every healthcare payment transaction. InstaMed’s patented, private cloud-based technology securely transforms healthcare payments by driving electronic transactions, processing payments and moving healthcare data seamlessly, and improving consumer satisfaction. Consumers, providers and payers benefit from InstaMed’s exclusive focus on healthcare, integration into any healthcare IT system, robust analytics and proven scale.

Read More